Janssen and Alligator Bioscience to develop immuno-oncology therapy

Janssen Biotech has announced a new immuno-oncology-focused collaboration with Alligator Bioscience.

The exclusive worldwide license agreement with Alligator Bioscience pertains to the development of ADC-1013, an agonistic fully human monoclonal antibody currently in phase I clinical studies.

ADC-1013 targets CD40, an immuno-stimulatory receptor found on antigen-presenting cells such as dendritic cells. Stimulating this receptor initiates a process leading to an increase in T cells attacking tumours.

Janssen will attain rights to develop and commercialise ADC-1013 once Alligator Bioscience completes the current phase I dose escalation study. In return, Alligator Bioscience will receive an upfront payment plus additional milestone fees.

Dr Peter Lebowitz, global oncology head for Janssen research and development, said: "ADC-1013 is a great addition to our growing immuno-oncology portfolio, which includes a broad range of approaches in both solid tumours and haematologic malignancies."

In a separate transaction, Janssen's parent company Johnson and Johnson has announced that it will subscribe for new shares of Alligator stock.